NCT06554184

HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

A Randomized Phase III Study Evaluating the Efficacy and Safety of HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 706 (actual)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is aimed to evaluate the efficacy and safety of HR20013 versus palonosetron for nausea and vomiting associated with moderate emetic risk anticancer agents

Conditions

• Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Interventions

Type	Name	Description
DRUG	HR20013 + dexamethasone + palonosetron placebo	HR20013 + dexamethasone + palonosetron placebo
DRUG	Palonosetron + dexamethasone + HR20013 placebo	Palonosetron + dexamethasone + HR20013 placebo

Timeline

• Start date: 2024-09-03
• Primary completion: 2025-07-28
• Completion: 2025-10-03
• First posted: 2024-08-15
• Last updated: 2025-11-17

Locations

1 site across 1 country: China